Intellia Therapeutics Inc. (NASDAQ: NTLA) announced the pricing of a public offering of 16.7 million shares of common stock at $10.75 per share. The Cambridge, Massachusetts-based gene editing company expects to raise approximately $180 million in gross proceeds before underwriting discounts and offering expenses.

The biopharmaceutical company granted underwriters a 30-day option to purchase up to 2.5 million additional shares at the same price, minus underwriting discounts and commissions. Jefferies, Goldman Sachs & Co. LLC and Citigroup serve as joint book-running managers for the offering.

Intellia is selling all securities in the offering through an automatic shelf registration statement filed with the Securities and Exchange Commission in November 2023. A preliminary prospectus supplement was filed with the SEC on April 27, with the final prospectus supplement expected to be filed separately.

The company focuses on CRISPR gene editing technology and developing treatments for severe diseases. The offering remains subject to market conditions and completion cannot be assured.